# Chronic Myeloid Leukemia Treatments

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/chronic-myeloid-leukemia-treatments/

## Facts

| Field | Value |
| --- | --- |
| Description | This cluster of papers focuses on the efficacy and resistance of various tyrosine kinase inhibitors, such as Imatinib, Dasatinib, and Nilotinib, in the treatment of Chronic Myeloid Leukemia (CML). The papers discuss molecular mechanisms of resistance, mutation analysis, leukemia stem cells, treatment discontinuation, and long-term outcomes of different targeted therapies. |
| Domain | Health Sciences |
| Field | Medicine |
| OpenAlex ID | t11215 |
| Works | 153 |

## Topic papers all

Showing 15 of 153.

- [Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain](https://scholariq.org/papers/acquired-resistance-of-lung-adenocarcinomas-to-gefitinib-or-erlotinib-is/)
- [Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer](https://scholariq.org/papers/crizotinib-in-i-ros1-i-rearranged-non-small-cell-lung-cancer/)
- [Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis](https://scholariq.org/papers/analysis-of-flt3-activating-mutations-in-979-patients-with-acute-myelogenous/)
- [Doxorubicin pathways](https://scholariq.org/papers/doxorubicin-pathways/)
- [European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia](https://scholariq.org/papers/european-leukemianet-2020-recommendations-for-treating-chronic-myeloid-leukemia/)
- [Intensive Postremission Chemotherapy in Adults with Acute Myeloid Leukemia](https://scholariq.org/papers/intensive-postremission-chemotherapy-in-adults-with-acute-myeloid-leukemia/)
- [Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma](https://scholariq.org/papers/lenalidomide-bortezomib-and-dexamethasone-with-transplantation-for-myeloma/)
- [EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors](https://scholariq.org/papers/eml4-alk-mutations-in-lung-cancer-that-confer-resistance-to-alk-inhibitors/)
- [Cardiotoxicity of the cancer therapeutic agent imatinib mesylate](https://scholariq.org/papers/cardiotoxicity-of-the-cancer-therapeutic-agent-imatinib-mesylate/)
- [The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage](https://scholariq.org/papers/the-tyrosine-kinase-c-abl-regulates-p73-in-apoptotic-response-to-cisplatin/)
- [Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society](https://scholariq.org/papers/baseline-cardiovascular-risk-assessment-in-cancer-patients-scheduled-to-receive/)
- [Fusion Between Transcription Factor CBFβ/PEBP2β and a Myosin Heavy Chain in Acute Myeloid Leukemia](https://scholariq.org/papers/fusion-between-transcription-factor-cbf-pebp2-and-a-myosin-heavy-chain-in-acute/)
- [Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring <i>c-Kit</i> Mutation or Amplification](https://scholariq.org/papers/phase-ii-open-label-single-arm-trial-of-imatinib-mesylate-in-patients-with/)
- [A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial](https://scholariq.org/papers/a-treatment-protocol-for-infants-younger-than-1-year-with-acute-lymphoblastic/)
- [Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial](https://scholariq.org/papers/discontinuation-of-tyrosine-kinase-inhibitor-therapy-in-chronic-myeloid/)

## Topic primary papers

Showing 15 of 55.

- [European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia](https://scholariq.org/papers/european-leukemianet-2020-recommendations-for-treating-chronic-myeloid-leukemia/)
- [Cardiotoxicity of the cancer therapeutic agent imatinib mesylate](https://scholariq.org/papers/cardiotoxicity-of-the-cancer-therapeutic-agent-imatinib-mesylate/)
- [The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage](https://scholariq.org/papers/the-tyrosine-kinase-c-abl-regulates-p73-in-apoptotic-response-to-cisplatin/)
- [Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial](https://scholariq.org/papers/discontinuation-of-tyrosine-kinase-inhibitor-therapy-in-chronic-myeloid/)
- [TGF-β–FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia](https://scholariq.org/papers/tgf-foxo-signalling-maintains-leukaemia-initiating-cells-in-chronic-myeloid/)
- [A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer](https://scholariq.org/papers/a-common-bim-deletion-polymorphism-mediates-intrinsic-resistance-and-inferior/)
- [Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia](https://scholariq.org/papers/cost-sharing-and-adherence-to-tyrosine-kinase-inhibitors-for-patients-with/)
- [The P190, P210, and P230 Forms of the <i>BCR/ABL</i> Oncogene Induce a Similar Chronic Myeloid Leukemia–like Syndrome in Mice but Have Different Lymphoid Leukemogenic Activity](https://scholariq.org/papers/the-p190-p210-and-p230-forms-of-the-i-bcr-abl-i-oncogene-induce-a-similar/)
- [Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia](https://scholariq.org/papers/requirement-of-src-kinases-lyn-hck-and-fgr-for-bcr-abl1-induced-b-lymphoblastic/)
- [Critical role for Gab2 in transformation by BCR/ABL](https://scholariq.org/papers/critical-role-for-gab2-in-transformation-by-bcr-abl/)
- [Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up](https://scholariq.org/papers/chronic-myeloid-leukaemia-esmo-clinical-practice-guidelines-for-diagnosis/)
- [High‐dose methotrexate‐induced nephrotoxicity in patients with osteosarcoma](https://scholariq.org/papers/high-dose-methotrexate-induced-nephrotoxicity-in-patients-with-osteosarcoma/)
- [Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial](https://scholariq.org/papers/discontinuation-of-dasatinib-in-patients-with-chronic-myeloid-leukaemia-who-have/)
- [Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia](https://scholariq.org/papers/loss-of-the-alox5-gene-impairs-leukemia-stem-cells-and-prevents-chronic-myeloid/)
- [Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/chronic-myeloid-leukemia-version-1-2019-nccn-clinical-practice-guidelines-in/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.